Efficacy of Incobotulinum toxin-A for the treatment of masseter muscle hypertrophy in Asian Indian patients: A 2-year follow-up study

Abstract

Background: With the changing trends, more and more patients are opting for non-
surgical or minimally invasive options for reshaping the face. Noninvasive treat-
ments such as incobotulinumtoxinA (Xeomin Cosmetic®; Merz Pharma Canada Ltd.,

Burlington, ON, Canada) are a preferred modality for reducing the volume of the
muscle and therefore reducing the width of masseter.
Aims: To evaluate the efficacy of Xeomin treatment in long-term management of
bilateral masseter hypertrophy in Asian Indian patients.

Patients/Methods: A total of 30 patients were enrolled in the study and were in-
jected with 30 U Xeomin on each side of face, at baseline. Fifteen patients received a

second session of Xeomin injection at 12th week, and remaining 15 patients received

an additional third session, at 12th and 24th weeks post the first injection, respec-
tively. Follow-up was done at 4th-, 12th-, 24th-, and 36th-week and at first- and

second-year follow-ups.
Results: For the patients who received two injections, the maximum reduction of
26.85% was observed at 24th week, which was maintained as 20.04% reduction until
second follow-up year. The patients who received three injections exhibited very
high reduction of 43.12% of masseter volume at 36th week, which was maintained
at 38.72 % until the second follow-up year. Three sessions of Xeomin injections were
proved to be more effective in long-term maintenance of reduced masseter volume
than 2 sessions of injections.
Conclusions: Xeomin injections were found to be effective in long-term management
of bilateral masseter hypertrophy. This is the first of its kind paper, which evaluates
the long-term effects of Xeomin injections for the treatment of masseter hypertrophy.

For full article open PDF